Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Airatovich Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,Boris Y. Alekseev,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Anna Kryzhanivska,Igor Bondarenko,Sergio J. Azevedo,Delphine Borchiellini,Cezary Szczylik,Maurice Markus,Raymond S McDermott,Jens Bedke,Sophie Tartas,Yen-Hwa Chang,Satoshi Tamada,Qiong Shou,Rodolfo F. Perini,Mei Chen,Michael B. Atkins,Thomas Powles

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

2019

Abstract Background The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether p...

Keywords:

Oncology
Axitinib
Diabetes mellitus
Surgery
Renal cell carcinoma
Pembrolizumab
Internal medicine
Medicine
Sunitinib
Progression-free survival
Clinical trial
Carcinoma
Survival rate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

1141

Citations